Harvard Bioscience, Inc. — FY2023 Form 10-K
Business context and reporting period. Harvard Bioscience (Nasdaq: HBIO) develops, manufactures and sells life-science research and preclinical-testing products, software and services worldwide. Its product families are Cellular and Molecular Technologies (CMT) and Preclinical. This annual report covers the fiscal year ended December 31, 2023; it does not provide standalone fourth-quarter results.
Key financial results
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $112.25 million | $113.34 million |
| Gross profit / margin | $66.07 million / 58.9% | $60.82 million / 53.7% |
| Operating income (loss) | $1.89 million | $(6.93) million |
| Net loss | $(3.42) million | $(9.52) million |
| Basic and diluted loss per share | $(0.08) | $(0.23) |
| Cash provided by operating activities | $14.03 million | $1.15 million |
| Cash and cash equivalents at year-end | $4.28 million | $4.51 million |
| Debt borrowings at year-end | $37.1 million | $47.7 million |
FY2023 cash used in investing activities was $1.80 million and cash used in financing activities was $12.13 million. The company reported $10.8 million of unused revolving-credit capacity, subject to a leverage-based borrowing limit. The weighted-average borrowing rate, including interest-rate swaps, was 7.4% at year-end. Current assets were $49.04 million and current liabilities were $26.54 million.
Changes versus FY2022
- Revenue declined 1.0%. Discontinued non-strategic products reduced revenue by $5.0 million, largely offset by growth in Preclinical products and services; foreign exchange added $0.7 million.
- Gross margin rose 5.2 percentage points, primarily from a richer mix of Preclinical products, services and software, lower-margin product discontinuations, and the absence of FY2022’s $1.5 million inventory write-down.
- Operating results improved to income from a loss, while net loss narrowed. Operating expenses declined, but interest expense increased 40.9% to $3.59 million amid higher rates.
- Operating cash flow rose substantially. FY2022 operating cash flow was affected by an approximately $4.0 million payment related to the HRGN litigation settlement.
- Debt borrowings fell by approximately $10.6 million. FY2023 financing cash outflows included $4.1 million of term-loan repayments and $6.45 million of net revolver repayments.
Outlook, commentary and risks
- Management expects available cash, operating cash generation and debt capacity to fund current operations and capital expenditures for at least 12 months, based on current plans. No specific revenue or earnings guidance is provided.
- Management cited softening in some international markets, especially China and Asia-Pacific; delayed government funding; and reduced biotech and pharmaceutical customer spending associated with higher capital costs and post-pandemic spending patterns. Demand associated with COVID-19 research is not expected to recur at prior levels.
- Debt totaled $37.1 million and the credit facility matures December 22, 2025. The company was in covenant compliance at year-end; a $2.1 million excess-cash-flow payment was due by March 31, 2024. Failure to meet covenants or refinance or repay obligations could affect liquidity and operations.
- Other notable risks include competition and rapid technology change, customer research-budget constraints, inflation and interest rates, foreign exchange exposure, international and supply-chain risks, and cybersecurity or IT disruptions. The company reported no material business impact from cybersecurity incidents to date and does not hedge foreign-currency exposures with forward contracts.
- The company completed its product rationalization and restructuring program, recording $0.4 million of additional inventory, severance and other charges in FY2023. It sold the Hoefer product line in February 2023 for $0.5 million and recorded a $0.4 million gain.
- The company held HRGN common stock valued at $3.5 million at year-end and recorded a $0.6 million unrealized loss in FY2023. The filing warns the investment could fluctuate considerably or become worthless. The HRGN litigation settlement resolved claims between the parties; other ordinary-course claims and an unclaimed-property audit remain disclosed without significant accruals.
- In February 2024, the company received and recorded $3.1 million under the Employee Retention Credit program. The filing also notes leases at several principal facilities expire in 2024.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting; no critical audit matters were identified. The filing corrected immaterial prior-period classifications within accumulated other comprehensive loss, with no effect on previously reported total OCI, equity, earnings or cash flows.
Important facts for investors to verify
- Review the credit agreement’s covenants, leverage-based revolver availability, required 2024 payments and 2025 maturity, including the company’s refinancing options.
- Assess whether operating cash generation is sustainable given low year-end cash, continuing net losses, customer spending trends and working-capital needs.
- Track whether Preclinical growth and higher gross margins can offset revenue pressure and the effects of discontinued products.
- Confirm the status and cash-flow treatment of the $3.1 million Employee Retention Credit received in February 2024, and any related tax or valuation-allowance implications.
- Monitor renewal or relocation plans for facilities with leases expiring in 2024, and the valuation and liquidity of the HRGN investment.
- Consult the full financial statements and notes for detailed debt, tax, pension, litigation and geographic disclosures; the filing’s statements about future funding adequacy are forward-looking and subject to risks.